Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEBATE
2023-504340-34-01Phase 4Authorised
- Sponsor
- Siun Sote
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised trial of aspirin, clopidogrel, prasugrel and ticagrelor in coronary arteriosclerosis, acute coronary syndrome (ACS), unstable angina and 1 more (2 arms), sponsored by Siun Sote. Primary endpoint: Composite of MACE and BARC type 2–5 bleeding at 12 months. Planned start Jan 2024; status: authorised.
02
Drugs
aspirinclopidogrelprasugrelticagrelor
03
Conditions
coronary arteriosclerosisacute coronary syndrome (ACS)unstable anginaNon-ST-segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on 2023-504340-34-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504340-34-01.